Hyperkalemia: a modern view on the problem and the possibilities of therapy (part 1)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The first part of the review systematizes modern data on the balance of potassium in the body, frequency, the main causes of development, and clinical manifestations of hyperkalemia in patients with renal dysfunction.

Full Text

Restricted Access

References

  1. Fleet J.L., Shariff S.Z., Gandhi S., Weir M.A., Jain A.K., Garg A.X. Validity of the international classification of disease 10th revision code of hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012; 2: e002011.
  2. Einhorn L.M., Zhan M., Hsu V.D., Walker L.D., Moen M.F., Seliger S.L., Weir M.R., Fink J.C. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 2009; 169: 1156-1162.
  3. Sarafidis P.A., Blacklock R., Wood E., Rumjon A., Simmonds S., Fletcher-Rogers J., Ariyanayagam R., Al-Yassin A.,.Sharpe C., Vinen K. Prevalence and factors associated with hyperkalemiain predialysispatients followed in a low-clearance clinic. Clin. J. Am. SocNephrol. 2012; 7: 1234-1241. клиническая нефрология № 2 - 2017
  4. Hayes J., Kalantar-Zadeh K., Lu J.L., Turban S., Anderson J.E., Kovesdy C.P. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron. Clin. Pract. 2012; 120: 8-16.
  5. Каюков И.Г., Куколева Л.Н., Зверьков Р.В., Эмануэль В.Л., Добронравов В.А., Смирнов А.В. Гомеостаз калия на различных стадиях хронической болезни почек. Нефрология и диализ. 2013; 4: 326.
  6. Epstein M., Reaven N.L., Funk S.E., McGaughey K.J., Oestreicher N., Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am. J. Manag. Care. 2015; 21: 212-220.
  7. Kovesdy C.P., Regidor D.L., Mehrotra R., Jing J., McAllister C.J., Greenland S., Kopple J.D., Kalantar-Zadeh K. Serum and dialysate potassium concentrations and survivalin hemodialysis patients. Clin. J. Am. SocNephrol. 2007; 2: 999-1007.
  8. Palmer B.F. Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N. Engl. J. Med. 2004; 351: 585-592.
  9. Goyal A., Spertus J.A., Gosh K., Venkitachalam L., Jones P.G., Van den Berghe G., Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012; 307: 157-164.
  10. Collins A.J., Reaven N., Funk S. Potassium levels and mortality in patients with CKD. J. Am. SocNephrol. 23014,25: 270A.
  11. Pun P.N., Lehrich R.W., Honeycutt E.F., Herzog C.A., Middleton J.P. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011; 79: 218-227.
  12. Shearer F., Lang C.C., Struthers A.D. Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin. Pharmacol. Ther. 2013; 94: 459-467.
  13. Hsu T.W., Liu J.S., Hung S.C. Kuo K.L., Chang Y.K., Chen Y.C., Hsu C.C., Tarng D.C. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension and anemia. JAMA Intern. Med. 2014; 174: 347-354.
  14. Xie X., Liu I., Prekovic V., Li X., Ninomiya T., Hou W., Zhao N., Liu L., Lv J., Zhang H., Wang H. Renin-angiotensin inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network metaanalysis of randomized clinical trials [e-pab ahead of print]. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2015.10.011
  15. The CONSENSUS Trial Study Group. Effects of enalaprilon mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Eng. J. Med. 1987; 316: 1429-1435.
  16. Шилова Е.М., Смирнова А.В., Козловской Н.Л. Нефрология. Клинические рекомендации. 2016.
  17. Krum H., Shi H., Pitt B., McMurray J., Swedberg K., van Veldhuisen D.J., Vincent J., Pocock S., Zannad F. Eplerenone in patients with systolic heart failure and mild symptoms. N. Eng. J. Med. 2011; 364: 11-21.
  18. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Eng. J. Med. 2004; 351: 1296-1305.
  19. Taler S.J., Agarwal R., Bakris G.L. Flynn J.T., Nilsson P.M., Rahman M., Sanders P.W., Textor S.C., Weir M.R., Townsend R.R. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am. J. Kidney Dis. 2013; 62: 201-213.
  20. Yildirim T., Arici M., Piskinpasa S., Aybal-Kutlugun A., Yilmaz R., Altun B., Erdem Y., Turgan C. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren. Fail. 2012; 34: 1095-1099.
  21. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. For the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibitions versus enalapril in heart failure. N. Engl. J. Med. 2014,371: 9931004.
  22. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
  23. Jadoul M., Thumma J., Fuller D.S., Tentori F., Li Y., Morgenstern H., Mendelssohn D., Tomo T., Ethier J., Port F., Robinson B.M. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice pattern study. Clin. J. Am. Soc. Nephrol. 2012; 7: 765-774.
  24. Palmer B.F. Regulation of potassium homeostasis. Clin. J. Am. SocNephrol. 2015; 10: 1050-1060.
  25. Samson S.C., Welling P.A. Two channels for one job. Kidney Int. 2007; 72: 529-530.
  26. Giebish G., Krapf R., Wagner C. Renal and extrarenal regulation of potassium. Kidney Int. 2007; 72: 397-410.
  27. Rabinowitz L., Green D.M., Sarason R.L., Yamauchi H. Homeostatic potassium excretion in fed and fasted sheep. Am. J. Physiol 1988; 254: 357-380.
  28. Calo L., Borsatti A., Favaro S., Rabinovitz L. Kaliuresis in normal subject following oral potassium citrate intake without increased plasma potassium concentration. Nephrol. 1995; 69: 253-258.
  29. Preston R.A., Afshartous D., Rodco R., Alonso A.B., Garg D. Evidence for a gastrointestinal kaliuretic signaling axis in humans. Kidney Int. 2015; 88: 1383-1391.
  30. Tsuchiya Y., Nakashima S., Banno Y., Suzuki Y., Morita H. Effect of high-NaCl or high-KCl diet on hepatic Na+ and K+ receptor sensitivity and NKCC1 expression in rats. Am. J. Physiol Regul. Integr. Comp. Physiol 2004; 286: R591-R596.
  31. Lee F.N., Oh G., McDonough A.A., Youn J.H. Evidence for gut factor in K homeostasis. Am. J. Physiol. Renal. Physiol. 2007; 293: F541-F547.
  32. Oh K.S., Oh Y.T., Kim S.V., Kita T., Kang I., Youn J.H. Cut sensing of dietary K+ intake increases renal K+ excretion. Am. J. Physiol Regul. Integr. Comp. Physiol. 2011; 301: R421-R429.
  33. El Mogharabi S., Houillier P., Picard N., Sohet F., Wootla B., Bloch-Faure M., Leviel F., Cheval L., Frische S., Meneton P., Eladari D., Chambrey R. Tissue kallikrein permits early renal adaptation to potassium load. Proc. Natl. Acad. Sci. USA 2010; 107: 13526-13531.
  34. Susa K., Sohara E., Isobe K., Chiga M., Rai T., Sasaki S., Uchida S. WNK-OSR1/SPAK-NCC signal cascade has circadian rhythm dependent on aldosterone. Biochem. Biophys. Res. Commun. 2012; 427: 743-747.
  35. Zuber A.M., Centeno G., Pradervand S., Nikolaeva S., Maquelin L., Cardinaux L., Bonny O., Firsov D. Molecular clock is involved in predictive circadian adjustment of renal function. Proc Natal. 2009; 106(38): 16523-16528.
  36. Sandle G.I., Geiger E., Tapster S., Goodship T.H. Evidence for large intestinal control of potassium homeostasis in uraemic patients undergoing long-term dialysis. Clin. Sci. (Lond).1987; 73: 247-252.
  37. Meng Q.H., Wagar E.A. Pseudohyperkalemia: a new twist on an old phenomenon. Crit. Rev. Clin. Lab. Sci. 2015; 52: 45-55.
  38. Seimiya M., Yoshida T., Sawabe Y., Sogawa K., Umemura H., Matsushita K., Nomura F. Reducing the incidence of pseudohyperkalemia by avoiding making a fist during phlebotomy: a quality improvement report. Am. J. Kidney Dis. 2010; 56: 686-692.
  39. Bailey I.R., Thurlow V.R. Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann. Clin. Biochem. 2008; 45: 266-269.
  40. Parham W.A., Mehdirad A.A., Biermann K.M., Fredman C.S. Hyperkalemia revisited. Tex. Heart. Inst. J. 2006; 33: 40-47.
  41. Mattu A., Brady W.J., Robinson D.A. Electrocardiographic manifestations of hyperkalemia. Am. J. Emerg. Med. 2000; 18: 721-729.
  42. Wrenn K.D., Slovis C.M., Slovis B.S. The ability of physicians to predict hyperkalemia from the ECG. Ann. Emerg. Med. 1991; 20: 1229-1232.
  43. Martinez-Vea A., Bardaji A., Garcia C., Oliver J.A. Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases. J. Electrocardiol. 1999; 32: 45-49, 31-34.
  44. Green D., Green H.D., New D.I., Kalra P.A. The clinical significance of hyperkalaemia associated repolarization abnormalities in end-stage renal disease. Nephrol. Dial. Transplant. 2013; 28: 99-105.
  45. Barold S.S., Herweg B. The effect of hyperkalaemia on cardiac rhythm devices. Europace. 2014; 16: 467-476.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies